Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 2/2002

01.12.2002 | Review Article

Pharmacoeconomic Considerations in the Management of Smoking Cessation

verfasst von: Christine Godfrey, Godfrey Fowler

Erschienen in: Drugs | Sonderheft 2/2002

Einloggen, um Zugang zu erhalten

Abstract

Smokers are more likely to develop a variety of serious diseases than nonsmokers; the morbidity and mortality from these diseases place a great resource burden on society in respect of demands on healthcare resources and lost productivity.
The cost to the healthcare system of treating the consequences of smoking is high. Given the availability of inexpensive pharmaceutical therapies such as sustained-release bupropion (bupropion SR) and nicotine replacement therapy (NRT), which are proven to be effective, there is economic advantage for governments and the medical profession in encouraging patients to quit. The cost effectiveness of effective smoking cessation support is far superior to that of many other potentially life-saving interventions and, indeed, the UK National Institute for Clinical Excellence (NICE) stated in April 2002 that ‘both bupropion and NRT are considered to be amongst the most effective of all healthcare interventions’. Recent economic analyses have confirmed that the use of bupropion SR as an aid to smoking cessation is a highly cost-effective intervention.
Fußnoten
1
Tradenames are used for identification purposes only and do not imply endorsement.
 
Literatur
1.
US Department of Health and Human Services. Reducing tobacco use: a report of the surgeon general. Atlanta (GA). Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000
2.
NHS Centre for Reviews and Dissemination. Smoking Cessation: what the health service can do. Effectiveness Matters 1998; 3(1): 4
3.
The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA 2000; 283: 3244–54CrossRef
4.
Lightwood JM, Phibbs CS, Glantz SA. Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics 1999; 104(6): 1312–20PubMedCrossRef
5.
Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997; 96: 1089–96PubMedCrossRef
6.
World Bank. Curbing the epidemic: governments and the economics of tobacco control [report]. Washington (DC): World Bank, 1999
7.
US Public Health Service. Treating tobacco use and dependence. US Public Health Service, 2000
8.
Bartlett JC, Miller LS, Rice DP, et al. Medical-care expenditures attributable to cigarette smoking -United States. 1993 Morb Mortal Wkly Rep 1994; 43(26): 469–72
9.
Miller LS, Zhang X, Rice DP, et al. State estimates of total medical expenditures attributable to cigarette smoking, 1993 [abstract]. Public Health Rep 1998; 113: 447–58PubMed
10.
Miller VP, Ernst C, Collin F. Smoking: attributable medical care costs in the USA. Soc Sci Med 1999; 48(3): 375–91PubMedCrossRef
11.
Buck D, Godfrey C, Parrott S. Cost effectiveness of smoking cessation interventions. London: Health Education Authority, 1997
12.
Buck D, Godfrey C. Helping smokers give up: guidance for purchasers on cost-effectiveness. London: Health Education Authority, 1994
13.
Collins D, Lapsley HM. The economic costs generated by tobacco use in Australia. Department of Human Services and Health submission to the Industry Commission Inquiry into the tobacco growing and manufacturing industries. Canberra: Commonwealth Department of Human Services and Health, 1994
14.
Kaiserman MJ. The cost of smoking in Canada, 1991. Chronic Dis Can 1997; 18: 13–9PubMed
15.
Jin SG, Lu BY, Yan DY, et al. An evaluation on smoking-induced health costs in China (1988–1989). Biomed Environ Sci 1995; 8: 342–9PubMed
16.
Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax 1998; 53 Suppl 5 (Pt 2): S1–38PubMedCrossRef
17.
Ruff L, Volmer T, Novak D, et al. The economic impact of smoking in Germany. Eur Respir J 2000; 16: 385–90PubMedCrossRef
18.
Phillips D, Kawachi I, Tilyard M. The economics of smoking: an overview of the international and New Zealand literature. Pharmacoeconomics 1993; 3: 462–70PubMedCrossRef
19.
Sanner T. What does cigarette smoking cost society?. [in Norwegian]. Tidsskr Nor Laegeforen 1991; 111(28): 3420–2PubMed
20.
Buck D. The cost-effectiveness of smoking cessation interventions: what do we know? Int J Health Educ 1997; 35: 44–52
21.
Centers for Disease Control and Prevention. Medical-care expenditures attributable to cigarette smoking: United States, 1993. Morb Mortal Wkly Rep 1994; 43: 469–72
22.
Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the United States: estimates, their validity, and their implications. Tob Control 1999; 8(3): 290–300PubMedCrossRef
23.
Buck D, Godfrey C, Raw M, et al. Tobacco and jobs: the impact of reducing consumption on employment in the UK. York: Society for the Study of Addiction, Centre for Health Economics, 1995
24.
Drever F, Whitehead M, editors. Health inequalities: decennial supplement: Office for National Statistics. London: The Stationery Office, 1997. Series DS: no. 15
25.
Office for National Statistics. Living in Britain: results from the 1998 general household survey. London: The Stationery Office, 2000
26.
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91PubMedCrossRef
27.
World Health Organization. International statistical classification of diseases and related health problems (ICD-10). 10th rev, vol 1. Geneva: World Health Organization, 1992
28.
West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987–99PubMedCrossRef
29.
Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15(3): 369–90PubMedCrossRef
30.
Warner KE. Cost-effectiveness of nicotine replacement therapy. Proceedings of Future Directions in Nicotine Replacement Therapy meeting; 1993 Oct; Paris. Chester (UK): Adis International, 1993: 35–40
31.
Warner KE. Cost effectiveness of smoking-cessation therapies: interpretation of the evidence and implications for coverage. Pharmacoeconomics 1997; 11(6): 538–49PubMedCrossRef
32.
Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997; 278(21): 1759–66PubMedCrossRef
33.
Stapleton JA, Lowin A, Russell MAH. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999; 354: 208–13CrossRef
34.
Wasley MA, McNagny SE, Phillips VL, et al. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997; 26: 264–70PubMedCrossRef
35.
Halpern MT, Khan ZM, Young TL, et al. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm 2000; 57: 1421–9PubMed
36.
Nielsen K, Fiore MC. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med 2000; 30: 209–16PubMedCrossRef
37.
38.
Musin A, Perez I, Anton E, et al. Impact of Zyntabac on morbidity, mortality and health care costs due to smoking in Spain [abstract]. 8th Annual Meeting of the Society for Research on Nicotine and Tobacco; 2002 Feb 20–23; Savannah (GA)
39.
Britton J, Bates C, Channer K, et al. The management of nicotine addiction: nicotine addiction in Britain. London: Royal College of Physicians of London, 2000
40.
Eddy DM. David Eddy ranks the tests. Harv Health Lett 1992; 17(9): 10–11
Metadaten
Titel
Pharmacoeconomic Considerations in the Management of Smoking Cessation
verfasst von
Christine Godfrey
Godfrey Fowler
Publikationsdatum
01.12.2002
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe Sonderheft 2/2002
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200262002-00007

Weitere Artikel der Sonderheft 2/2002

Drugs 2/2002 Zur Ausgabe

Review Article

The Epidemiology of Smoking

Review Article

Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation

Review Article

Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation

Review Article

Current Approaches to the Management of Smoking Cessation

Review Article

Clinical Efficacy of Bupropion in the Management of Smoking Cessation

Review Article

Use of Sustained-Release Bupropion in Specific Patient Populations for Smoking Cessation